National and State Estimates of SELECT Trial Eligibility and Its Public Health Impact in the US
Open Access
- 1 July 2024
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (7) , e2420105
Abstract
In the US, approximately two-thirds of adults are classified as overweight or obese, conditions linked to increased risks of hypertension, type 2 diabetes, and cardiovascular disease (CVD).1 The SELECT (Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity) trial showed that a weight loss dose of semaglutide significantly reduces the incidence of major adverse CVD outcomes in nondiabetic individuals who are either overweight or obese.2 Building on research highlighting variations in the cardiometabolic disease burden across states,3 this study examines the potential impact of the SELECT trial nationally and by state.Keywords
This publication has 4 references indexed in Scilit:
- Eligibility for Cardiovascular Risk Reduction Therapy in the United States Based on SELECT Trial Criteria: Insights From the National Health and Nutrition Examination SurveyCirculation: Cardiovascular Quality and Outcomes, 2024
- Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesNew England Journal of Medicine, 2023
- Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart AssociationCirculation, 2021
- Geographic Variation in Cardiovascular Health Among American AdultsMayo Clinic Proceedings, 2021